Testing NPX887 for advanced solid tumors with B7-H7 protein
Part of Cancer clinical trials.
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of solid tumor cancer (like lung, kidney, colorectal, stomach, bile duct, or ovarian) that has spread or come back after standard treatments stopped working.
- Your tumor must have a protein called B7-H7 (HHLA2) on its surface. This can be checked on a stored tumor sample.
- You are able to get around and take care of yourself (ECOG score 0-2).
- You haven't had cancer treatment (chemo, targeted therapy, or radiation) in the last 1-2 weeks, and any side effects from prior treatments have mostly resolved.
- You do not have active or growing brain metastases, and you have not had severe lung or colon inflammation from prior immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug (MX006) in people with advanced or metastatic tumors that have a specific marker called B7-H3. The drug may work by targeting this marker to stop cancer growth. The study aims to see if MX006 is safe and effective in this patient group.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Hear when a new Metastatic Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.